ATE244763T1 - Erzielen von homozygotem durch zielgerichtete genetische ereignisse - Google Patents

Erzielen von homozygotem durch zielgerichtete genetische ereignisse

Info

Publication number
ATE244763T1
ATE244763T1 AT93905784T AT93905784T ATE244763T1 AT E244763 T1 ATE244763 T1 AT E244763T1 AT 93905784 T AT93905784 T AT 93905784T AT 93905784 T AT93905784 T AT 93905784T AT E244763 T1 ATE244763 T1 AT E244763T1
Authority
AT
Austria
Prior art keywords
homozygote
achievement
marker gene
targeted genetic
genetic events
Prior art date
Application number
AT93905784T
Other languages
English (en)
Inventor
Jonathan G Seidman
Aya Jakobovits
Original Assignee
Cell Genesys Inc
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc, Harvard College filed Critical Cell Genesys Inc
Application granted granted Critical
Publication of ATE244763T1 publication Critical patent/ATE244763T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
AT93905784T 1992-02-11 1993-02-02 Erzielen von homozygotem durch zielgerichtete genetische ereignisse ATE244763T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83399292A 1992-02-11 1992-02-11
PCT/US1993/000926 WO1993016177A1 (en) 1992-02-11 1993-02-02 Homogenotization of gene-targeting events

Publications (1)

Publication Number Publication Date
ATE244763T1 true ATE244763T1 (de) 2003-07-15

Family

ID=25265825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93905784T ATE244763T1 (de) 1992-02-11 1993-02-02 Erzielen von homozygotem durch zielgerichtete genetische ereignisse

Country Status (7)

Country Link
US (1) US5589369A (de)
EP (1) EP0626012B1 (de)
JP (1) JP3571337B2 (de)
AT (1) ATE244763T1 (de)
CA (1) CA2128862C (de)
DE (1) DE69333082T2 (de)
WO (1) WO1993016177A1 (de)

Families Citing this family (262)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
WO1992020808A1 (en) * 1991-05-15 1992-11-26 Cell Genesys, Inc. Genomic modifications with homologous dna targeting
US20020108136A1 (en) * 1997-03-21 2002-08-08 Sri Transgenic animals produced by homologous sequence targeting
EP0733059B1 (de) * 1993-12-09 2000-09-13 Thomas Jefferson University Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
US5731181A (en) * 1996-06-17 1998-03-24 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
US6924146B1 (en) * 1997-02-21 2005-08-02 Sigrid Wattler Method of constructing vectors for homologous recombination directed mutagenesis
US5948653A (en) * 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
KR100856995B1 (ko) 1997-04-07 2008-09-04 제넨테크, 인크. 인간화 항체 및 인간화 항체의 제조 방법
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US6194633B1 (en) 1998-01-26 2001-02-27 University Of Iowa Research Foundation Non-human animal having a functionally disrupted SLP-76 gene
EP1637160A3 (de) 1999-05-07 2006-05-03 Genentech, Inc. Behandlung von Autoimmunkrankheiten mit Antagonisten die Oberflächenmarker von B Zellen binden
DE60042066D1 (de) 1999-05-28 2009-06-04 Genentech Inc Chimärische dr4 antikörper und ihre verwendung
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ES2329437T3 (es) 1999-06-25 2009-11-26 Genentech, Inc. Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
BRPI0017590B8 (pt) 1999-06-25 2021-05-25 Genentech Inc conjugado de maitansinoide - anticorpo anti-erbb, e formulação farmacêutica
AU2756301A (en) * 2000-01-03 2001-07-16 Panagenic International, Inc. Compositions comprising genome segments and methods of using the same
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
AU2001261650A1 (en) * 2000-05-15 2001-11-26 Geron Corporation Ovine tissue for xenotransplantation
WO2001097858A2 (en) 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
EP1303293B1 (de) 2000-07-27 2008-12-03 Genentech, Inc. Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
CN1468250A (zh) * 2000-08-03 2004-01-14 ��ķһ����˹��̹ 在转基因动物中产生人源化抗体
WO2002022834A2 (en) * 2000-09-15 2002-03-21 Deltagen, Inc. Methods of producing cells and animals comprising targeted gene modifications
CN1592645A (zh) * 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
JP2005503999A (ja) 2001-01-31 2005-02-10 アイデック ファーマスーティカルズ コーポレイション 腫瘍性疾患の治療のためのｃｄ２３拮抗剤の使用
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020132340A1 (en) * 2001-03-09 2002-09-19 Todd Waldman Isogenic beta-catenin cell lines, and methods of making and using same
JP2005508608A (ja) 2001-03-22 2005-04-07 アボット ゲーエムベーハー ウント カンパニー カーゲー 問題遺伝子に対して特異的な抗体を発現するトランスジェニック動物及びその使用
CA2442801A1 (en) * 2001-04-02 2002-10-10 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with gntiii
CA2481515C (en) 2002-04-10 2013-10-01 Genentech, Inc. Anti-her2 antibody variants
PT1585966E (pt) 2002-07-15 2012-02-20 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 rhumab 2c4
EP1581648A2 (de) * 2002-09-09 2005-10-05 Nura, Inc. G-protein-gekoppelte rezeptoren und deren verwendung
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
CA2505994A1 (en) 2002-11-15 2004-06-03 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
CA2513113A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP2902491A1 (de) 2003-03-19 2015-08-05 Biogen MA Inc. NOGO Rezeptor bindendes Protein
NZ587776A (en) 2003-04-09 2012-03-30 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1629001A2 (de) 2003-06-05 2006-03-01 Genentech, Inc. Blys-antagonisten und deren verwendung
WO2005037999A2 (en) * 2003-10-14 2005-04-28 Biogen Idec Ma Inc. Treatment of cancer using antibodies to lrrc15
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JP2008504002A (ja) 2003-11-12 2008-02-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法
PL2311873T3 (pl) 2004-01-07 2019-01-31 Novartis Vaccines And Diagnostics, Inc. Przeciwciało monoklonalne specyficzne wobec M-CSF i jego zastosowania
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
BRPI0509412A (pt) * 2004-04-16 2007-09-04 Genentech Inc método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado
KR101200133B1 (ko) 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
TW201422238A (zh) 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
EP1776136B1 (de) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Behandlung von entmyelinisierenden erkrankungen
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
US20060063187A1 (en) * 2004-09-15 2006-03-23 Hotamisligil Gokhan S Modulation of XBP-1 activity for treatment of metabolic disorders
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006055836A2 (en) * 2004-11-16 2006-05-26 President And Fellows Of Harvard College In vivo alteration of cellular dna
EP2311880A3 (de) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto-bindende Moleküle
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
ZA200707078B (en) 2005-02-23 2008-11-26 Genentech Inc Extending time to disease progression or survival in cancer patients
CA2602777C (en) 2005-03-25 2018-12-11 Tolerrx, Inc. Gitr binding molecules and uses therefor
MX2007013673A (es) * 2005-05-04 2008-03-10 Tmo Renewables Ltd Microorganismos termofilicos con el gen lactato deshidrogenasa (ldh) inactivado para produccion de etanol.
GB0511602D0 (en) * 2005-06-07 2005-07-13 Tmo Biotec Ltd Microorganisms
JP5372500B2 (ja) * 2005-06-17 2013-12-18 トレラクス リクイデーティング トラスト Ｉｌｔ３結合分子およびその使用
EP1917020B1 (de) 2005-07-07 2016-05-25 Seattle Genetics, Inc. Monomethylvalin-verbindungen mit phenylalanin-seitenketten-modifikationen am c-terminus
US8871720B2 (en) * 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
MX2008000253A (es) 2005-07-08 2008-04-02 Biogen Idec Inc Anticuerpos de sp35 y usos de los mismos.
WO2007016285A2 (en) * 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
JP5657862B2 (ja) * 2005-07-28 2015-01-21 ノバルティス アーゲー Ｍ−ｃｓｆに対する抗体の使用
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
CA2628451A1 (en) 2005-11-04 2007-05-18 Biogen Idec Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2627446A1 (en) * 2005-11-21 2007-05-31 Laboratoires Serono S.A. Compositions and methods of producing hybrid antigen binding molecules and uses thereof
EP2543384A3 (de) 2005-12-02 2013-04-10 Biogen Idec MA Inc. Behandlung von Zuständen mithilfe von Demyelinisation
US9155762B2 (en) * 2005-12-08 2015-10-13 University Of Louisville Research Foundation, Inc. Uses and isolation of stem cells from bone marrow
EP1974018A4 (de) * 2005-12-08 2010-01-27 Univ Louisville Res Found Vsel (very small embryonic-like)-stammzellen und verfahren zur isolierung und verwendung davon
PL2481753T3 (pl) 2005-12-13 2018-09-28 Eli Lilly And Company Przeciwciała anty-IL-17
EP2526968A3 (de) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo-Rezeptorantagonisten
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
SG170728A1 (en) 2006-03-23 2011-05-30 Novartis Ag Anti-tumor cell antigen antibody therapeutics
EP2010226B1 (de) * 2006-04-07 2014-01-15 The Research Foundation of State University of New York Transcobalaminrezeptor-Polypeptide, -Nukleinsäuren und -Modulatoren sowie entsprechende Verfahren zur Verwendung für die Modulation von Zellwachstum und die Behandlung von Krebs und Cobalaminmangel
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
EP2041180B8 (de) * 2006-06-19 2014-03-05 Liquidating Trust Ilt3-bindende moleküle und verwendungen davon
ES2612383T3 (es) 2006-07-19 2017-05-16 The Trustees Of The University Of Pennsylvania WSX-1/IL-27 como una diana para respuestas antiinflamatorias
CA2659820A1 (en) * 2006-08-04 2008-02-14 Novartis Ag Ephb3-specific antibody and uses thereof
SI2059535T1 (sl) * 2006-08-18 2014-03-31 Novartis Ag Za prlr specifiäśno protitelo in njegove uporabe
EP2423332A1 (de) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognosemarker und therapeutische Targets für Lungenkrebs
ATE536374T1 (de) 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
US20080076139A1 (en) 2006-09-21 2008-03-27 Sharat Singh Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
MX2009002296A (es) * 2006-09-28 2009-04-16 Tmo Renewables Ltd Microorganismos termofilicos para la produccion de etanol.
AU2007313822A1 (en) * 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US7829674B2 (en) 2006-10-27 2010-11-09 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate
EA200900767A1 (ru) 2006-12-07 2009-12-30 Новартис Аг Антагонистические антитела против ephb3
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
AU2007333635B2 (en) 2006-12-20 2014-02-20 Xoma (Us) Llc Treatment of IL-1-beta related diseases
US20080171344A1 (en) * 2006-12-22 2008-07-17 Kapsner Kenneth P Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
PT2740744T (pt) 2007-01-09 2018-06-06 Biogen Ma Inc Anticorpos sp35 e suas utilizações
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
JP2010517529A (ja) 2007-02-02 2010-05-27 アムジエン・インコーポレーテツド ヘプシジン及びヘプシジン抗体
DK2132573T3 (da) 2007-03-02 2014-07-14 Genentech Inc Forudsigelse af respons på en her-dimeriseringsinhibitor på basis af lav her3-ekspression
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
SI2155248T1 (sl) 2007-04-12 2015-12-31 The Brigham And Women's Hospital, Inc. Ciljanje ABCB5 za zdravljenje raka
JP5989299B2 (ja) * 2007-05-30 2016-09-07 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． リゾホスファチジン酸結合のための組成物と方法
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
CA2917355C (en) 2007-06-08 2018-07-17 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
ES2528167T3 (es) 2007-06-15 2015-02-04 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Tratamiento de tumores usando anticuerpo anti-L1, específico.
DK2175884T3 (en) * 2007-07-12 2016-09-26 Gitr Inc Combination USING GITR BINDING MOLECULES
GB0715751D0 (en) 2007-08-13 2007-09-19 Tmo Renewables Ltd Thermophilic micro-organisms for ethanol production
EP2198021A4 (de) 2007-08-24 2011-01-19 Oncotherapy Science Inc Ebi3, dlx5, nptx1 und cdkn3 für zielgene der lungenkrebstherapie und -diagnose
ES2565202T3 (es) 2007-10-16 2016-04-01 Zymogenetics, Inc. Combinación de activador transmembrana y modulador de calcio e interactor de ligando de ciclofilina (TACI) y agentes anti-CD20 para tratamiento de enfermedades autoinmunitarias
US8361465B2 (en) 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
EP2214497A4 (de) * 2007-10-30 2010-11-24 Univ Louisville Res Found Verwendungen und isolation von vsel (very small embryonic-like) stammzellen
CN101970689A (zh) 2007-11-29 2011-02-09 健泰科生物技术公司 炎性肠病的基因表达标志物
MX2010006823A (es) 2007-12-20 2010-09-30 Xoma Technology Ltd Metodos para el tratamiento de la gota.
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (de) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
CA2711826C (en) 2008-01-25 2018-02-27 Amgen Inc. Ferroportin antibodies and methods of use
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
ES2553390T3 (es) 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
CA2719201A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc. Neutralizing molecules to viral antigens
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
EP2323679A4 (de) 2008-07-25 2012-08-22 Univ Colorado Clip-hemmer und verfahren zur modulierung der immunfunktion
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
GB0820262D0 (en) * 2008-11-05 2008-12-10 Tmo Renewables Ltd Microorganisms
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
WO2010065921A2 (en) * 2008-12-05 2010-06-10 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US20120027722A1 (en) 2008-12-17 2012-02-02 Medical Research Council Hepatitis c virus combination therapy
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
AU2009334498A1 (en) 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
AU2010226392B9 (en) 2009-03-20 2014-05-22 Amgen Inc. Selective and potent peptide inhibitors of Kv1.3
AU2010228990A1 (en) 2009-03-24 2011-10-27 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against LIGHT and uses thereof
ES2627909T3 (es) 2009-07-15 2017-08-01 Diatech Holdings, Inc. Selección de fármacos para el tratamiento del cáncer gástrico usando matrices basadas en anticuercuerpos
EP2456890A1 (de) 2009-07-20 2012-05-30 Genentech, Inc. Genexpressionsmarker für morbus crohn
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CA2772945A1 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
EP2491385B1 (de) 2009-10-20 2017-05-10 DiaTech Holdings, Inc. Proximitätsvermittelte tests für den nachweis von onkogenen fusionsproteinen
CA2781532A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP3299380B1 (de) 2010-05-25 2024-08-28 F. Hoffmann-La Roche AG Verfahren zur aufreinigung von polypeptiden
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
KR20130097747A (ko) 2010-08-10 2013-09-03 암젠 인크 표적 항체에 대한 중화 항체의 검출을 위한 이중 기능 시험관내 표적 결합 분석평가
EA201370076A1 (ru) 2010-09-22 2013-08-30 Амген Инк. Иммуноглобулины-переносчики и их применение
KR102116202B1 (ko) 2010-11-08 2020-05-28 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
US20140199682A1 (en) 2010-11-17 2014-07-17 Sea Lane Biotechnologies, Llc Influenza neutralizing agents
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
AR084020A1 (es) 2010-11-30 2013-04-17 Genentech Inc Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos
WO2012075333A2 (en) 2010-12-02 2012-06-07 Prometheus Laboratories Inc. Her2delta16 peptides
KR20140002711A (ko) 2010-12-23 2014-01-08 네스텍 소시에테아노님 항체-기반 어레이를 사용한 악성 암 치료를 위한 약물 선별법
CA2823707A1 (en) 2011-01-18 2012-07-26 Amgen Inc. Nav1.7 knockout mice and uses thereof
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
AU2012261933B2 (en) 2011-06-03 2017-06-15 Xoma Technology Ltd. Antibodies specific for TGF-beta
HUE043894T2 (hu) 2011-06-10 2019-09-30 Bioverativ Therapeutics Inc Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013033623A1 (en) 2011-09-02 2013-03-07 Nestec S.A. Profiling of signal pathway proteins to determine therapeutic efficacy
PT3257564T (pt) 2011-11-02 2019-03-22 Hoffmann La Roche Cromatografia de eluição e sobrecarga
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
WO2013106577A2 (en) 2012-01-10 2013-07-18 Biogen Idec Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
US20150201588A1 (en) 2012-02-22 2015-07-23 Amgen Inc. Autologous Mammalian Models Derived from Induced Pluripotent Stem Cells and Related Methods
KR102142161B1 (ko) 2012-05-14 2020-08-06 바이오젠 엠에이 인코포레이티드 운동 뉴런 관련 병태 치료용 lingo-2 길항제
JP6254581B2 (ja) 2012-05-18 2017-12-27 ジェネンテック， インコーポレイテッド 高濃度モノクローナル抗体製剤
KR102031317B1 (ko) 2012-05-21 2019-10-14 제넨테크, 인크. 혈액-뇌 장벽 수송의 안전성을 개선하는 방법
HUE043552T2 (hu) 2012-06-08 2019-09-30 Sutro Biopharma Inc Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
EP2863955B1 (de) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modifizierte fc-proteine mit nichtnatürlichen ortsspezifische aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
PL2890712T3 (pl) 2012-08-29 2019-09-30 F.Hoffmann-La Roche Ag Przenośnik wahadłowy przez barierę krew-mózg
JP2015537212A (ja) 2012-11-15 2015-12-24 ジェネンテック， インコーポレイテッド イオン強度媒介のｐｈ勾配イオン交換クロマトグラフィー
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
EP4324480A3 (de) 2013-05-20 2024-05-08 F. Hoffmann-La Roche AG Anti-transferrin-rezeptor-antikörper und verfahren zur verwendung
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
BR112016000231A8 (pt) 2013-07-12 2019-12-31 Genentech Inc métodos para identificações de condições de separação com cromatografia de troca de íons e para análises de composições de polipeptídeos
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
CA2922832A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Method for chromatography reuse
JP6886816B2 (ja) 2013-09-09 2021-06-16 カニムガイド セラピューティックス アーベー 免疫系調節薬
IL320195A (en) 2013-09-13 2025-06-01 Genentech Inc Methods and compositions containing purified recombinant polypeptides
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
EP3521431A1 (de) 2013-09-25 2019-08-07 Cornell University Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
EP4331590A3 (de) 2013-10-29 2024-04-17 President and Fellows of Harvard College Verfahren und zusammensetzungen zur hemmung von oxidativem stress
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
EP3104882B1 (de) 2014-02-14 2019-06-05 Centrose, Llc Extrazelluläre gezielte wirkstoffkonjugate
EP3708227A1 (de) 2014-07-22 2020-09-16 Sutro Biopharma, Inc. Anti-cd74-antikörper, zusammensetzungen mit anti-cd74-antikörpern und verfahren zur verwendung von anti-cd74-antikörpern
ES2962385T3 (es) 2014-10-15 2024-03-18 Amgen Inc Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas
CN107001473B (zh) 2014-11-19 2021-07-09 豪夫迈·罗氏有限公司 抗-运铁蛋白受体抗体及使用方法
US11008403B2 (en) 2014-11-19 2021-05-18 Genentech, Inc. Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
CN107207591A (zh) 2014-12-10 2017-09-26 豪夫迈·罗氏有限公司 血脑屏障受体抗体及使用方法
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
EP3265117B1 (de) 2015-03-06 2020-11-11 CanImGuide Therapeutics AB Immunsystemmodulatoren und -zusammensetzungen
EP3277716B1 (de) 2015-04-03 2020-06-24 XOMA Technology Ltd. Behandlung von krebs unter verwendung von inhibitoren von tgf-beta und pd-1
CN107646038B (zh) 2015-05-28 2021-08-20 基因泰克公司 用于检测抗cd3同二聚体的基于细胞的测定
PL3303619T3 (pl) 2015-05-29 2020-10-05 F. Hoffmann-La Roche Ag Metylacja promotora PD-L1 w chorobach nowotworowych
EP3331562A2 (de) 2015-08-06 2018-06-13 Xoma (Us) Llc Antikörperfragmente gegen den insulinrezeptor und verwendungen davon zur behandlung von hypoglykämie
WO2017062682A2 (en) 2015-10-06 2017-04-13 Genentech, Inc. Method for treating multiple sclerosis
WO2017087901A2 (en) 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
US11513127B2 (en) 2016-01-25 2022-11-29 Genentech, Inc. Methods for assaying T-cell dependent bispecific antibodies
WO2017132617A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
EP3472197A1 (de) 2016-06-15 2019-04-24 Sutro Biopharma, Inc. Antikörper mit manipulierten ch2-domänen, zusammensetzungen davon und verfahren zur verwendung davon
CN118530358A (zh) 2016-08-01 2024-08-23 佐马美国有限公司 甲状旁腺激素受体1（pth1r）抗体和其用途
HRP20250718T1 (hr) 2016-08-15 2025-08-15 F. Hoffmann-La Roche Ag Kromatografski postupak za kvantifikaciju neionskog surfaktanta u sastavu koji sadrži neionski surfaktant i polipeptid
CN110087681A (zh) 2016-09-28 2019-08-02 佐马美国有限公司 结合白细胞介素-2的抗体和其用途
US20190233512A1 (en) 2016-10-12 2019-08-01 Sutro Biopharma, Inc. Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
EP3585813A1 (de) 2017-02-22 2020-01-01 Sutro Biopharma, Inc. Pd-1/tim-3 bi-spezifische antikörper, zusammensetzungen davon und verfahren zur herstellung und verwendung davon
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
US20200079850A1 (en) 2017-05-24 2020-03-12 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
US10961318B2 (en) 2017-07-26 2021-03-30 Forty Seven, Inc. Anti-SIRP-α antibodies and related methods
US20200207859A1 (en) 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
KR20200051802A (ko) 2017-09-18 2020-05-13 서트로 바이오파마, 인크. 항-엽산 수용체 알파 항체 접합체 및 이의 용도
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
WO2019190969A1 (en) 2018-03-26 2019-10-03 Sutro Biopharma, Inc. Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
WO2019195561A2 (en) 2018-04-06 2019-10-10 BioLegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
WO2019200397A1 (en) 2018-04-13 2019-10-17 Chan Zuckerberg Biohub, Inc. Compositions and methods for modulating left-right differentiation factor (lefty) and bone morphogenic factor (bmp)
US20220047716A1 (en) 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
WO2020068557A1 (en) 2018-09-25 2020-04-02 BioLegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
US11208487B2 (en) 2018-09-27 2021-12-28 Tizona Therapeutics Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies
CA3115077A1 (en) 2018-10-09 2020-04-16 Ibex Biosciences, Llc Antibodies directed to filamin-a and therapeutic uses thereof
JP2022514290A (ja) 2018-12-20 2022-02-10 ジェネンテック， インコーポレイテッド 改変抗体ｆｃおよび使用方法
US20230242660A1 (en) 2019-02-21 2023-08-03 Trishula Therapeutics, Inc. Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies
CN113711037A (zh) 2019-04-18 2021-11-26 基因泰克公司 抗体效力测定
US20220323599A1 (en) 2019-05-03 2022-10-13 Celgene Corporation Anti-bcma antibody conjugate, compositions comprising the same, and methods of making and using the same
WO2020227105A1 (en) 2019-05-03 2020-11-12 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
EP3969906A1 (de) 2019-05-16 2022-03-23 ProciseDx Inc. Assay-nachweisverfahren für vcam-1 und calprotectin
JP2022532385A (ja) 2019-05-16 2022-07-14 プロサイセデクス インコーポレイティド 血中のＶＣＡＭ－１及びα２－マクログロブリンの検出のためのアッセイ方法
WO2020236528A1 (en) 2019-05-23 2020-11-26 Procisedx Inc. Assay methods for the detection of human serum albumin, vitamin d, c-reactive protein, and anti-transglutaminase autoantibody
TWI870412B (zh) 2019-06-05 2025-01-21 美商建南德克公司 過載層析管柱之再生方法
EP3980779A1 (de) 2019-06-06 2022-04-13 ProciseDx Inc. Nachweis von hämoglobin a1c (hba1c) in blut
JP7706210B2 (ja) 2019-06-10 2025-07-11 ストロ バイオファーマ インコーポレーテッド ５Ｈ－ピロロ［３，２－ｄ］ピリミジン－２，４－ジアミノ化合物およびその抗体コンジュゲート
EP3983410A1 (de) 2019-06-17 2022-04-20 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-aminderivate und verwandte verbindungen als toll-like- rezeptor (tlr) 7/8-agonisten sowie antikörper-wirkstoff-konjugate davon zur verwendung in der krebstherapie und -diagnose
WO2020263450A1 (en) 2019-06-25 2020-12-30 Procisedx Inc. Detection of anti-tnf alpha drug biologics and anti-drug antibodies
WO2021146383A1 (en) 2020-01-17 2021-07-22 BioLegend, Inc. Anti-tlr7 agents and compositions and methods for making and using the same
JP2023518814A (ja) 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Ｃｏｖｉｄ－１９肺炎における、ｉｌ－６アンタゴニストに対する応答を予測するためのバイオマーカー
EP4107184A1 (de) 2020-03-23 2022-12-28 Genentech, Inc. Verfahren zur behandlung von pneumonie, einschliesslich covid-19-pneumonie, mit einem il6-antagonisten
JP2023518812A (ja) 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Ｃｏｖｉｄ１９肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ
WO2021222533A1 (en) 2020-04-30 2021-11-04 Procisedx Inc. Methods of detecting antibodies to sars-cov-2
EP4168115A1 (de) 2020-06-22 2023-04-26 The Board of Trustees of the Leland Stanford Junior University Tsp-1-inhibitoren zur behandlung von gealtertem, atrophietem oder dystrophietem muskel
JP2023541921A (ja) 2020-09-17 2023-10-04 ジェネンテック， インコーポレイテッド Ｃｏｖｉｄ－１９肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験（ｅｍｐａｃｔａ）の結果
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
KR20240004659A (ko) 2021-04-30 2024-01-11 셀진 코포레이션 감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
EP4340876A1 (de) 2021-05-19 2024-03-27 Sutro Biopharma, Inc. Kombinationstherapie mit anti-folat-rezeptorkonjugaten mit bevacizumab
CA3221924A1 (en) 2021-06-11 2022-12-15 Genentech, Inc. Method for treating chronic obstructive pulmonary disease with an st2 antagonist
JP2024534265A (ja) 2021-08-23 2024-09-18 イミュニタス セラピューティクス，インコーポレーテッド 抗ｃｄ１６１抗体及びその使用
KR20240108799A (ko) 2021-12-01 2024-07-09 서트로 바이오파마, 인크. 항 엽산 수용체 접합체 암 요법
WO2023104904A2 (en) 2021-12-08 2023-06-15 Genclis The sars-cov-2 and variants use two independent cell receptors to replicate
KR20240165358A (ko) 2022-04-01 2024-11-22 제넨테크, 인크. 폴리펩티드를 안정화하기 위한 하이드록시프로필 메틸 셀룰로오스 유도체
AU2023295035A1 (en) 2022-06-17 2024-08-15 Genentech, Inc. Use of kosmotropes to enhance yield of an affinity chromatography purification step
EP4558523A1 (de) 2022-07-19 2025-05-28 Biolegend, Inc. Anti-cd157-antikörper, antigenbindende fragmente davon sowie zusammensetzungen und verfahren zur herstellung und verwendung davon
US20260042848A1 (en) 2022-08-18 2026-02-12 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
WO2025021790A2 (en) 2023-07-24 2025-01-30 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2025054320A1 (en) 2023-09-05 2025-03-13 Tizona Therapeutics Anti-ackr4 antibodies, compositions and uses thereof
WO2025080711A1 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Dual payload antibody drug conjugates
US12540197B2 (en) 2023-10-13 2026-02-03 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
WO2025199118A1 (en) 2024-03-18 2025-09-25 Willow Neuroscience, Inc. Anti-trem1 antibody constructs, compositions comprising anti-trem1 antibody constructs and methods of using anti-trem1 antibody constructs
WO2025213047A1 (en) 2024-04-05 2025-10-09 Tizona Therapeutics, Inc. Anti-il-18bp antibodies, compositions comprising anti-il-18bp antibodies and methods of using anti-il-18bp antibodies
WO2025250825A1 (en) 2024-05-30 2025-12-04 Sutro Biopharma, Inc. Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
US20260053942A1 (en) 2024-05-30 2026-02-26 Astellas Pharama Inc. Sting agonist immunostimulatory antibody drug conjugates
WO2026020051A1 (en) 2024-07-19 2026-01-22 Nurix Therapeutics, Inc. Bifunctional compounds for degrading aurora kinase via ubiquitin proteosome pathway
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA

Also Published As

Publication number Publication date
DE69333082D1 (de) 2003-08-14
CA2128862C (en) 2008-05-20
WO1993016177A1 (en) 1993-08-19
JP3571337B2 (ja) 2004-09-29
EP0626012A4 (en) 1996-01-03
JPH07503848A (ja) 1995-04-27
US5589369A (en) 1996-12-31
DE69333082T2 (de) 2004-05-06
EP0626012A1 (de) 1994-11-30
EP0626012B1 (de) 2003-07-09
CA2128862A1 (en) 1993-08-19

Similar Documents

Publication Publication Date Title
ATE244763T1 (de) Erzielen von homozygotem durch zielgerichtete genetische ereignisse
Clark Invasion and maintenance of a gene duplication.
DK1032680T3 (da) En hidtil ukendt metode til integration af fremmed DNA ind i eukaryote genomer
Broders et al. Population genetic structure and the effect of founder events on the genetic variability of moose, Alces alces, in Canada
Leitch et al. Genome size dynamics and evolution in monocots
DK0749444T3 (da) Human/dyre-faktor VIII-hybrid
Niwa et al. Growth arrest and chromosome instability in aneuploid yeast
Termolino et al. Insights into epigenetic landscape of recombination-free regions
Szymura et al. Concordant change in mitochondrial and nuclear genes in a hybrid zone between two frog species (genus Bombina)
Buss The uniqueness of the individual revisited.
Martins et al. Physical mapping of the Nile tilapia (Oreochromis niloticus) genome by fluorescent in situ hybridization of repetitive DNAs to metaphase chromosomes—a review
DE69635955D1 (de) Verbesserter einbau exogener dna in pflanzenzellen
Smith et al. Gene conversion shapes linear mitochondrial genome architecture
FI962268A0 (fi) Homologinen, rekombinanttinen vasta-aineilmentämisjärjestelmä rottien tai hiirien soluille
Wu et al. Mitochondrial‐encoded endonucleases drive recombination of protein‐coding genes in yeast
Sloan et al. Polyploid plants take cytonuclear perturbations in stride
AU2002252984A1 (en) Stress resistance as a selectable marker for transgenic plants
DE69013495D1 (de) Regulierung der genexpression.
Hosgood et al. The exploitation of genetic heterogeneity among the founders of laboratory populations of Drosophila prior to directional selection
Mlinarec et al. Structure and Methylation of 35S rDNA in Allopolyploids Anemone multifida (2 n= 4 x= 32, BBDD) and Anemone baldensis (2 n= 6 x= 48, AABBDD) and Their Parental Species Show Evidence of Nucleolar Dominance
BOULIKAS Functions of chromatin and the expression of genes
DK1082408T3 (da) I IRAK-genet modificerede transgene mus
Weil Too many ends: aberrant transposition
Mertens Teaching the concept of genetic drift using a simulation
IL142182A0 (en) Geminivirus resistant transgenic plants

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties